美罗华
医学
膜性肾病
蛋白尿
耐火材料(行星科学)
胃肠病学
内科学
自发缓解
抗体
免疫学
泌尿科
肾
病理
天体生物学
物理
替代医学
作者
Lihua Zhang,Mengxing Chen,Weibo Le,Mingchao Zhang,Yuanmao Tu,Ke Zuo,Dacheng Chen,Yan Wu,Shijun Li,Caihong Zeng,Cheng Zhang,Honglang Xie
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-10-01
卷期号:14 (15): 1237-1244
被引量:1
标识
DOI:10.2217/imt-2021-0044
摘要
Aims: To evaluate the efficacy of long-term repeated rituximab treatment in refractory PLA2R-Ab-related membranous nephropathy (MN). Materials & methods: Rituximab was administered at a single dose of 375 mg/m 2 and repeated if peripheral B-cell levels were >5/ul in 46 patients with refractory PLA2R-Ab-related MN. Results: The median frequency of rituximab treatment was 3 (IQR 2.0–4.0). A total of 32 (32/46) patients achieved remission (completed remission [CR] or partial remission [PR]) over a median time of 17.0 months, and 10 patients eventually progressed to CR. The proportion of serum PLA2R-Ab depletion was 73.91% (34/46) over a median time of 9 months. Antibody depletion preceded proteinuria remission. Conclusions: Long-term repeated rituximab treatment achieved high kidney and immunological response rates in refractory PLA2R-Ab related MN, and antibody depletion was a prerequisite for proteinuria remission.
科研通智能强力驱动
Strongly Powered by AbleSci AI